CN102311500B - 一种抗病毒融合蛋白及其应用 - Google Patents
一种抗病毒融合蛋白及其应用 Download PDFInfo
- Publication number
- CN102311500B CN102311500B CN201010216332.5A CN201010216332A CN102311500B CN 102311500 B CN102311500 B CN 102311500B CN 201010216332 A CN201010216332 A CN 201010216332A CN 102311500 B CN102311500 B CN 102311500B
- Authority
- CN
- China
- Prior art keywords
- vmip
- protein
- cell
- hiv
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 19
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 12
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 12
- 230000004927 fusion Effects 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 9
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 30
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract description 19
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract description 19
- 241000700605 Viruses Species 0.000 abstract description 16
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 15
- 208000030507 AIDS Diseases 0.000 abstract description 13
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 abstract description 9
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 230000003612 virological effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 2
- 230000007938 immune gene expression Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 23
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 239000012634 fragment Substances 0.000 description 9
- 230000029087 digestion Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000012797 qualification Methods 0.000 description 8
- 108010054167 vMIP-II Proteins 0.000 description 8
- JOEHPBQVSCDCHE-BKGQOYFSSA-N (4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1r)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound N1C(=O)[C@@H](N)CSSC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CC1=CC=CC=C1 JOEHPBQVSCDCHE-BKGQOYFSSA-N 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 description 6
- 102100040266 DNA dC->dU-editing enzyme APOBEC-3F Human genes 0.000 description 6
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 description 6
- 101000964377 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3F Proteins 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 5
- 108010088535 Pep-1 peptide Proteins 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 2
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 229940124522 antiretrovirals Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101150050516 APOBEC3G gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 102000005455 Monosaccharide Transport Proteins Human genes 0.000 description 1
- 108010006769 Monosaccharide Transport Proteins Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010216332.5A CN102311500B (zh) | 2010-07-02 | 2010-07-02 | 一种抗病毒融合蛋白及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010216332.5A CN102311500B (zh) | 2010-07-02 | 2010-07-02 | 一种抗病毒融合蛋白及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102311500A CN102311500A (zh) | 2012-01-11 |
CN102311500B true CN102311500B (zh) | 2015-05-27 |
Family
ID=45425093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010216332.5A Expired - Fee Related CN102311500B (zh) | 2010-07-02 | 2010-07-02 | 一种抗病毒融合蛋白及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102311500B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530241B (zh) * | 2014-12-15 | 2018-05-18 | 武汉市畜牧兽医科学研究所 | 一种表达穿膜肽融合蛋白的基因工程菌及应用 |
CN105985441A (zh) * | 2015-01-27 | 2016-10-05 | 长春百益制药有限责任公司 | 次血红素6肽衍生物及其制备方法和用途 |
EP3801029B1 (en) * | 2018-05-30 | 2024-07-10 | Morehouse School of Medicine | Antibacterial compositions, methods of making and use thereof |
US20220169680A1 (en) * | 2018-11-02 | 2022-06-02 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Cell-penetrating peptide based on influenza virus m2 protein |
CN109824769B (zh) * | 2019-02-14 | 2022-05-24 | 深圳市疾病预防控制中心 | 双翅肽b蛋白和/或双翅肽b基因的应用以及抗病毒药物 |
CN113604555B (zh) * | 2021-08-02 | 2023-05-23 | 中山大学 | 与h7n9禽流感易感性相关的标记物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1242236A (zh) * | 1999-07-13 | 2000-01-26 | 暨南大学 | Hhv8的mip同源物在防治艾滋病的药物中的应用 |
CN101343327A (zh) * | 2008-08-13 | 2009-01-14 | 汕头大学医学院 | 一种抗病毒蛋白质及其应用 |
-
2010
- 2010-07-02 CN CN201010216332.5A patent/CN102311500B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1242236A (zh) * | 1999-07-13 | 2000-01-26 | 暨南大学 | Hhv8的mip同源物在防治艾滋病的药物中的应用 |
CN101343327A (zh) * | 2008-08-13 | 2009-01-14 | 汕头大学医学院 | 一种抗病毒蛋白质及其应用 |
Non-Patent Citations (1)
Title |
---|
穿膜肽携带的目的蛋白穿膜效应的研究;严世荣;《中国优秀博士论文全文数据库》;20070915;摘要,实验部分 * |
Also Published As
Publication number | Publication date |
---|---|
CN102311500A (zh) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102311500B (zh) | 一种抗病毒融合蛋白及其应用 | |
Boshra et al. | Rift valley fever: recent insights into pathogenesis and prevention | |
JP7260170B2 (ja) | 事前の免疫化ステップのないhiv免疫療法 | |
JP7153332B2 (ja) | Hivワクチン接種および免疫療法 | |
KR101922539B1 (ko) | 종양 선택적 e1a 및 e1b 돌연변이 | |
JP7239948B2 (ja) | サイレント変異を有する組換えrsv、ワクチン、およびそれに関連する方法 | |
CN112618707A (zh) | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 | |
JP5690814B2 (ja) | 抗原特異的な免疫応答を高めるための組成物及び方法 | |
WO2009130618A2 (en) | Flagellin polypeptide vaccines | |
US10617729B2 (en) | Multitargeting onocolytic adenovirus, methods of use, and methods of making | |
CN105924530B (zh) | 嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用 | |
CN103224914A (zh) | 表达融合外源表位n蛋白的重组小反刍兽疫病毒的构建及应用 | |
Bolhassani et al. | Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses | |
CN101314047A (zh) | 治疗病毒感染的方法及其药物 | |
Stubbs et al. | Vesicular stomatitis virus chimeras expressing the Oropouche virus glycoproteins elicit protective immune responses in mice | |
CN105367661B (zh) | 嵌合抗原受体及其基因和重组表达载体、工程化her1靶向性的nkt细胞及其应用 | |
CA2991213A1 (en) | Recombinant virus like particles using bovine immunodeficiency virus gag protein | |
Kadkhodayan et al. | The efficiency of Tat cell penetrating peptide for intracellular uptake of HIV-1 Nef expressed in E. coli and mammalian cell | |
CN101475641A (zh) | 腺病毒载体禽流感重组疫苗 | |
Zhou et al. | Inhibition of replication of classical swine fever virus in a stable cell line by the viral capsid and Staphylococcus aureus nuclease fusion protein | |
WO2021207848A1 (en) | Mers-cov vaccine | |
Gautam et al. | Vesicular stomatitis virus-simian retrovirus type 2 vaccine protects macaques from detectable infection and B-cell destruction | |
CN102787119A (zh) | 治疗和/或预防病毒感染的产品及方法 | |
Schaecher et al. | SARS coronavirus accessory gene expression and function | |
Manfredi et al. | Induction of SARS-CoV-2 N-specific CD8+ T cell immunity in lungs by engineered extracellular vesicles associates with strongly impaired viral replication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201130 Address after: No.428, South Road, Haian street, Hai'an City, Nantong City, Jiangsu Province, 226600 Patentee after: Nantong Jiusi Medical Equipment Co.,Ltd. Address before: 226300 No. 266 Century Avenue, hi tech Zone, Jiangsu, Nantong Patentee before: NANTONG WOTE OPTOELECTRONICS TECHNOLOGY Co.,Ltd. Effective date of registration: 20201130 Address after: 226300 No. 266 Century Avenue, hi tech Zone, Jiangsu, Nantong Patentee after: NANTONG WOTE OPTOELECTRONICS TECHNOLOGY Co.,Ltd. Address before: Hangzhou City, Zhejiang province 310036 Xiasha Higher Education Park forest Street No. 16 Patentee before: Hangzhou Normal University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150527 |